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CONCISE REPORT
Risk factors for lung cancer in patients with scleroderma: a
nested case–control study
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Objectives: To study potential risk factors for the development
of lung cancer in patients with scleroderma and explore the
chronological relationship between onset of scleroderma
symptoms and subtypes of lung cancer.
Method: Linkage of two population-based registers to identify
lung cancer cases and gender-matched controls with sclero-
derma, followed by retrospective case note review for clinical
details.
Results: Patients with scleroderma who smoke are seven times
more likely to develop lung cancer than non-smokers
(p = 0.008). Smokers with scleroderma and cancer smoke
more than smokers with scleroderma without cancer
(p = 0.019). Pulmonary fibrosis and anti-topoisomerase anti-
body do not increase the risk of lung cancer. Peripheral lung
tumours occur earlier after the onset of scleroderma symptoms
than bronchogenic tumours (p = 0.05).
Conclusions: Smokers with scleroderma should be monitored
for the presence of lung cancer and counselled to quit smoking.
The earlier development of peripheral lung tumours is not
consistent, with pulmonary fibrosis being an aetiological factor.
M
ost, but not all, population-based studies of cancer in
scleroderma have shown an increased incidence of all
cancers and, most consistently, an increased risk of lung
cancer.1–4 The relationship between these two diseases remains
unclear. It has been suggested that the common link between
lung cancer and scleroderma is pulmonary fibrosis; however,
this has not been formally tested in a cohort study.5
METHODS
Scleroderma ascertainment
Patients with scleroderma were identified from the South
Australian Scleroderma Registry (SASR), which has been
described elsewhere.6 The registry was established in 1993
and aims to identify all residents with scleroderma in South
Australia (SA).
Patients were ascertained from hospital discharge indices,
state immunodiagnostic laboratories (all positive centromeres
and Scl-70 were pursued), referrals from SA rheumatologists
and other specialist clinics. Scleroderma was validated accord-
ing to the American Rheumatology Association criteria7 by
examining referring clinical letters, case notes and autopsy
reviews. Patients were subdivided into three clinical variants—
namely limited, diffuse or overlap scleroderma—according to
the extent of skin involvement and other criteria according to
LeRoy et al.8 Patients with localised scleroderma were not
included. Written consent was obtained from all patients before
confidential enrolment, and the registry’s use for analyses of
this type had the approval of human ethical committees of all
teaching hospitals in SA. Although complete ascertainment
cannot be guaranteed, a high ascertainment rate in our
population was inferred by the fact that scleroderma prevalence
in SA, a statistic derived from the SASR, was high when
compared with other regional world studies.6
Cancer ascertainment
There is compulsory notification of cancer in SA to the South
Australian Cancer Registry (SACR)9 from pathology labora-
tories, hospital medical record departments, radiotherapy
departments and oncologists, with 95% completeness verified
by multiple electronic searches of SA laboratory and hospital
records each year. In addition, the International Agency for
Research on Cancer checks the quality of the SACR data every
5 years.
Using Automatch software (Matchware Technologies,
Kenrebunk, Maine, USA), all subjects on the SASR were linked
to the SACR to identify all cases of lung cancer among these
patients prior to 1 January 2003. Case notes were then reviewed
for confirmation of lung cancer histology, presence of pulmon-
ary fibrosis and method of diagnosis, smoking history and year
of onset of scleroderma symptoms including Raynaud’s
phenomenon. Gender-matched controls were selected using
computer-generated random numbers from the remainder of
the SASR and their case notes similarly reviewed. Odds ratios
for risk factors for lung cancer in scleroderma were determined,
and categorical variables were analysed using x2, Fisher’s exact
and t tests.
RESULTS
There were 632 patients on the SASR as of 1 January 2003 and
20 lung cancers were identified in 19 of them (table 1). One
individual developed two histologically distinct tumours in
different lobes. The average age at diagnosis of cancer was
similar for all subtypes (squamous cell, mean 65.3 years; large
cell, 64.3 years; adenocarcinoma, 60.7 years; small cell,
65.3 years; and bronchoalveolar cell (BAC), 72.5 years). Of
those patients with lung cancer, 90% were smokers. Only two
patients were non-smokers, both of whom developed BAC.
There were 5 (20%) cases of PF in the patients with lung cancer
(2 squamous cell, 1 BAC, 1 large cell and 1 small cell lung
cancer).
Cigarette smoking was a risk factor for development of lung
cancer (table 2), with smokers being seven times more likely to
develop lung cancer than non-smokers. Having pulmonary
fibrosis, diffuse disease or being anti-topoisomerase antibody
positive did not increase the risk of lung cancer. Smokers with
scleroderma and lung cancer were more likely to smoke larger
quantities than controls with scleroderma who smoked. The
number of pack years (1 pack year = 20 cigarettes per day for 1
year) smoked was known for 15 of the 18 (83%) cases of lung
cancer in smokers, and in 18 of the 23 (78%) controls who
smoked. The average number of pack years in the smokers who
Abbreviations: SASR, South Australian Scleroderma Registry; SACR,
South Australian Cancer Registry
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developed cancer (46.7 years) was significantly greater than in
controls who smoked (29.6 years; p = 0.019).
All lung cancers occurred after onset of scleroderma
symptoms (fig 1). The median time to cancer after onset of
scleroderma symptoms was 25 years (range 1–39 years) for the
bronchogenic tumours (small and squamous cell) and 5 years
(range 1–33 years) for the peripheral tumours (large cell, BAC
and adenocarcinoma) (p = 0.05). Only two of the seven
bronchogenic tumours occurred early and both these patients
had pulmonary fibrosis, whereas none of those with adeno-
carcinoma did.
DISCUSSION
We have demonstrated a strong association between lung
cancer and heavier smoking in patients with scleroderma,
which is similar to that seen in the UK general population.10 We
found no association between lung cancer and pulmonary
fibrosis, scleroderma subtype or anti-topoisomerase status.
Furthermore, we have shown that peripheral lung tumours
occur earlier than bronchogenic tumours in the course of
scleroderma.
Three previous studies in the English literature have
considered potential risk factors for lung cancer in sclero-
derma.11–13 Similar but separate studies from Baltimore and
Ontario that prospectively followed a total of 319 scleroderma
outpatients found 10 patients who developed lung cancer, all of
whom had evidence of pulmonary fibrosis and three of whom
were smokers.11 12 In a single-centre study from the Pittsburgh
standard metropolitan statistical area,13 four cases of lung
cancer in 262 patients with scleroderma were identified. All had
evidence of pulmonary fibrosis and one was a smoker.
Conclusions regarding the lung cancer, smoking and pulmon-
ary fibrosis relationship in scleroderma are difficult to draw
from these studies owing to the lack of control groups and use
of outpatient-based rather than population-based registers. The
latter point is likely to lead to a higher proportion of patients
with PF and smaller numbers of those with cancer. Patients on
the SASR with diffuse scleroderma, the variant associated with
pulmonary fibrosis, make up 22%. This is a low figure compared
with many cohort studies, but reflects higher detection rates of
limited and mild disease in our population.6
Although our pulmonary fibrosis ascertainment methods are
similar to large cryptogenic fibrosing alveolitis cohorts14 and the
aforementioned scleroderma studies in which all patients with
lung cancer had pulmonary fibrosis, the investigation used to
demonstrate pulmonary fibrosis varies between patients in all
these cohorts. A smaller prospective study would eliminate this
variable, but lose the strength of complete cancer ascertain-
ment. CT and biopsy results were available in 75% of our cancer
cases, and although the prevalence of pulmonary fibrosis in our
control group may be underestimated, this would not diminish,
but would increase the significance of our findings. Data on
immunosuppressant therapy in this cohort were incomplete
and so not included, but this factor could potentially affect the
incidence of cancer.
We have previously seen no difference in proportions of lung
cancer subtypes in our cohort compared with the general SA
population.2 Peripheral lung cancers, however, occur earlier
after the onset of scleroderma symptoms than traditionally
smoking-related bronchogenic tumours. This contradicts the
Table 1 Characteristics of the patients with scleroderma and lung cancer
Lung cancer
histology
Age at onset of
scleroderma (years)










Squamous cell 58 59 .1 Unknown M Yes (CT) 100
Squamous cell 36 61 .25 L M Yes (CT) 30
Squamous cell 47 76 .29 L F no (CT) 50
Large cell 54 56 .2 L M Yes (biopsy) 40
Large cell Unknown 72 Unknown M No (CT) 12 cig/day
Large cell* 60 65 .5 L M No (CT) 60
Adenocarcinoma* 60 65 .5 L M No (CT) 60
Adenocarcinoma 58 62 .4 L F No (CT) 58
Adenocarcinoma 28 46 .18 D F No (PFT) 20 cig/day
Adenocarcinoma 57 58 .1 O F No (CT ) 25 cig/day
Adenocarcinoma 48 56 .8 L F No (CXR) 15
Adenocarcinoma 72 76 .4 O M No (CT) 50
Adenocarcinoma 29 62 .33 L F No (CT) 40
Small cell 51 57 .5 D M Yes (CT) 15
Small cell 26 65 .39 L F No (CT) 70
Small cell 50 72 .22 L F No (CXR) 40
Small cell 40 67 .27 L M No (CXR) 58
BAC 51 69 .18 L F Yes (CT) 0
BAC 60 76 .16 L F No (CT) 0
unspecified 62 81 .19 D F Unknown 14
BAC, bronchoalveolar carcinoma; CXR, chest x ray; D, diffuse; F, female; M, male; L, limited; O, overlap; PFT, pulmonary function testpack years (1 pack
year = 20 cigarettes per day for 1 year).
cig/day = number of cigarettes smoked per day, duration of smoking (years) unknown.
*Patient with two histologically distinct lung tumours.




Male 9 (45%) 19 (46.3%)
Mean age (years) 65 69 p.0.05, unpaired t test




for whom value is
known (table 1;
years)
46.7 29.6 p = 0.019, unpaired t
test
Pulmonary fibrosis 5 (25%) 11 (27%) OR 1.19, p = 1, Fisher’s
Diffuse
scleroderma
3 (15%) 7 (17%) OR 0.86, p = 1, Fisher’s
Anti-topoisomerase
antibody
0 (0%) 6 (14.6%)
Anti-centromere
antibody
3 (15%) 17(41.5%) p,0.001, x2square
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hypothesis of scleroderma-induced pulmonary fibrosis leading
to tumour development in the damaged lung as the time frame
is inconsistent and none of the patients with adenocarcinoma
had pulmonary fibrosis. A multitude of factors in a lung with
scleroderma, including cytokines and disturbance of cellular
immunity, may predispose an individual to peripheral tumours
as well as pulmonary fibrosis, the former being a cause of death
before the development of pulmonary fibrosis. Alternatively,
the dominance of smoking as a risk factor in our study suggests
that its effect may over-ride or synergise with that of
scleroderma, making the smoking pattern, including year of
cessation, important information to plot chronologically with
diagnosis of lung cancer and of scleroderma symptoms onset.
More detailed smoking histories are required and this
information should be collected prospectively in scleroderma
registries, followed by counselling to quit smoking. Different
histological types of cancer may represent a heterogeneous end
point and could also be a point for further study.
Using two population-based registries, we demonstrated a
strong association between lung cancer and heavier smoking in
patients with scleroderma. By contrast, we found no association
with pulmonary fibrosis, scleroderma subtype and anti-topoi-
somerase status. Scleroderma registers should prospectively
collect detailed smoking histories, and patients with sclero-
derma who smoke should be monitored for the presence of lung
cancer, and strongly encouraged to quit.
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Figure 1 Chronological relationship between onset of scleroderma symptoms and subtypes of lung cancer. 0, year of onset of scleroderma symptoms,
subsequent number = years after onset of scleroderma that lung cancer was diagnosed.
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